{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Unresectable+Melanoma", "query": { "condition": "Advanced Unresectable Melanoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 129, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Unresectable+Melanoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-21T17:12:08.354Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2001-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161187" }, { "nct_id": "NCT04598009", "title": "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-03-03", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 2, "location_summary": "La Jolla, California • San Francisco, California", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04598009" }, { "nct_id": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Cervical Cancer", "Non-small Cell Carcinoma", "Melanoma", "Ovarian Cancer", "Anogenital Cancers", "HPV - Anogenital Human Papilloma Virus Infection", "HPV-Related Cervical Carcinoma", "HPV-Related Carcinoma", "HPV-Related Squamous Cell Carcinoma", "HPV-Related Malignancy", "HPV-Related Adenocarcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Related Adenosquamous Carcinoma", "HPV-Associated Vaginal Adenocarcinoma", "HPV-Related Endocervical Adenocarcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Verrucous Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma", "HPV Positive Rectal Squamous Cell Carcinoma" ], "interventions": [ { "name": "TSC-204-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702 + TSC-202-A0201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-05-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973487" }, { "nct_id": "NCT03501368", "title": "Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Unresectable Melanoma", "Advanced Melanoma" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2018-06-27", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501368" }, { "nct_id": "NCT04572451", "title": "Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Unresectable Solid Tumors", "Neoplasms", "Neoplasms by Histologic Type", "Neoplasms by Site", "Antineoplastic Agents, Immunological", "Antineoplastic Agents", "Immune Checkpoint Inhibitors", "Molecular Mechanisms of Pharmacological Action", "Nivolumab" ], "interventions": [ { "name": "nivolumab", "type": "DRUG" }, { "name": "BMS-986253", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Yana Najjar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-11-29", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2025-08-01", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 2, "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572451" }, { "nct_id": "NCT02012231", "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Thyroid Cancer", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Histiocytosis", "Hairy Cell Leukemia" ], "interventions": [ { "name": "PLX8394", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fore Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-02", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012231" }, { "nct_id": "NCT01827111", "title": "Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Phone Call", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2013-04-25", "completion_date": "2020-09-21", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01827111" }, { "nct_id": "NCT03719131", "title": "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma, Stage III", "Cutaneous Melanoma, Stage IV", "Stage III Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-06-05", "completion_date": "2026-06-30", "has_results": true, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719131" }, { "nct_id": "NCT04091750", "title": "Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-03-02", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-07-21T17:12:08.354Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04091750" } ] }